FIELD: medicine.
SUBSTANCE: invention relates to the field of medicine and pharmacology and is aimed at treating triple-negative breast cancer. Proposed is a method for treating triple-negative breast cancer in a subject in need thereof, including administering a therapeutically effective amount of a compound represented by a structure by the formula XI(e), wherein R4 and R5 independently represent hydrogen, O-alkyl, O-haloalkyl, F, Cl, Br, I, haloalkyl, CN, -CH2CN, NH2, hydroxyl, -(CH2)iNHCH3, -(CH2)iNH2, -(CH2)iN(CH3)2, -OC(O)CF3, linear or branched C1-C5alkyl, alkylamino, aminoalkyl, -OCH2Ph, -NHCO-alkyl, COOH, -C(O)Ph, C(O)O-alkyl, C(O)H, -C(O)NH2, or NO2; i constitutes an integer from 0 to 5 and n constitutes an integer from 1 to 4, or a pharmaceutically acceptable salt, hydrate, or combination thereof, to the subject to cure triple-negative breast cancer.
EFFECT: ensured effective treatment of triple-negative breast cancer.
10 cl, 78 dwg, 2 tbl, 7 ex
| Title | Year | Author | Number |
|---|---|---|---|
| COMPOUNDS FOR TREATING CANCER | 2010 |
|
RU2581367C2 |
| COMPOUNDS FOR TREATING CANCER | 2011 |
|
RU2609018C2 |
| COMPOUNDS FOR CANCER TREATMENT | 2011 |
|
RU2762111C1 |
| COMPOUNDS FOR TREATMENT OF CANCER | 2015 |
|
RU2805949C2 |
| COMPOUNDS FOR TREATING CANCER | 2015 |
|
RU2733393C2 |
| COMPOUND FOR TREATING CANCER | 2014 |
|
RU2708247C2 |
| COMBINATION OF MCL-1 INHIBITOR AND TAXANE COMPOUND, THEIR APPLICATIONS AND PHARMACEUTICAL COMPOSITIONS | 2018 |
|
RU2763544C2 |
| COMPOUNDS FOR CANCER TREATMENT | 2009 |
|
RU2514427C2 |
| TRIHETEROCYLIC COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF AND METHODS FOR CANCER TREATMENT | 2004 |
|
RU2360913C2 |
| TRICYCLIC COMPOUNDS AS INHIBITORS OF IMMUNOSUPPRESSION MEDIATED BY TRYPTOPHAN METABOLIZATION | 2014 |
|
RU2667509C2 |
